MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...
Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock ...
Both 340B stakeholders endorsed an independent data clearinghouse and statutory patient definition amid program growth ...
FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma. The findings suggest twice yearly dosing may offer early ...
BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology. In one of its most recent pilots, AON partnered with Evolent Health and a specific ...
Type 2 (T2)-high and T2-low asthma are distinguishable by unique transcriptomic networks, but characterization of T2-low asthma remains relatively poo ...
CMS is accelerating downside risk in value-based care (VBC), even though many clinicians, practices, and health systems lack the operational and measurement infrastructure needed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results